NSI-189

Safety profile
Category: Experimental antidepressant and nootropic drug - human trials are underway but as yet incomplete - has not yet been approved by the FDA or any other governmental health body for human consumption.
Main effects: Reports of increased motivation and relief from depression, enhanced cognition.
Side effects: Undesirable side effects experienced by users include: parathesia, anxiety, headaches, insomnia, drowsiness

Brief overview - What is NSI-189?

From Wikipedia:

NSI-189 is an experimental drug being studied by Neuralstem, Inc.[1] Research into NSI-189 has been funded by the Defense Advanced Research Projects Agency (DARPA) and the National Institutes of Health (NIH) for the treatment of major depressive disorder.[2] [1]

Additional safety notes

Being a new and novel compound, information regarding reagent testing has not yet surfaced. The only way to be 100% sure of a positive identification would be mass spectroscopy. As with all substances, take at your own risk and start with a low dose, building up over time if desired.

IMPORTANT: Many early adopters of this compound like to take it sublingually. The author of this article sustained burns to the underside of his tongue resulting in peeling skin after around 10 minutes of exposure. This damage healed in a few days but served as a sufficient warning against sublingual administration in favour of oral.

Dosage/Regimen

Human trials were carried out in groups of 40mg, 80mg and 120mg per day. 120mg was found to be less beneficial than 40mg or 80mg. Most self-administered trials have been in the 5-40mg per day range, usually split into two doses at the beginning and end of the day, or a single dose at the beginning of the day to minimise insomnia. as mentioned above, some take it orally, some sublingually.

Since this drug regenerates atrophied brain tissue, some early adopters chose to experiment with daily administration for a month (to match the human trials), then stopping. Many report experiencing more benefits after stopping than during the dosing period.